CRL · Other

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-09

• Guidance and OutlookImportance 51 · Surprise 60
  Charles River Laboratories reduced its 2026 GAAP earnings guidance, indicating a lower expected full-year earnings outcome than previously communicated. The company also reported a quarterly net loss, reversing…

News · 2026-08-07

• Capital Return ProgramImportance 58 · Surprise 42
  Charles River repurchased $100.0 million of common stock during Q2 2026. Total repurchases reached $300.0 million year to date. The buybacks provided a material offset to dilution and represented the company’s…
• Market Demand TrendsImportance 17 · Surprise 24
  Charles River reported improving demand for drug discovery and development services, particularly from biotechnology clients. The Discovery and Safety Assessment (DSA) segment showed a strong recovery, with improved…
• NHP Supply SourcingImportance 17 · Surprise 24
  Discovery and Safety Assessment benefited from lower non-human-primate sourcing costs. The sourcing improvement supported DSA performance and suggests better supply availability or procurement conditions for non-human…

News · 2026-08-06

• Capital Return ProgramImportance 58 · Surprise 42
  Charles River repurchased $100.0 million of common stock during Q2 2026. Total repurchases reached $300.0 million year to date. The buybacks provided a material offset to dilution and represented the company’s…
• Market Demand TrendsImportance 17 · Surprise 24
  Charles River reported improving demand for drug discovery and development services, particularly from biotechnology clients. The Discovery and Safety Assessment (DSA) segment showed a strong recovery, with improved…

10-Q · 2026-08-05

• Liquidity and Debt PositionImportance 79 · Surprise 66
  Cash and cash equivalents totaled $192.0 million at June 27, 2026, down from $213.8 million at December 27, 2025. Total debt increased to $2.620 billion from $2.117 billion, including $1.120 billion outstanding under…
• Operating Expense TrendsImportance 72 · Surprise 74
  Six-month unallocated corporate costs increased $62.2 million, or 49.9%, to $187.0 million, raising corporate costs to 9.3% of revenue from 6.2%. The increase primarily reflected higher acquisition, integration, and…
• Acquisitions and DivestituresImportance 71 · Surprise 60
  Charles River acquired an additional 79% equity interest in PathoQuest SAS on April 17, 2026 for $67.6 million, funding the transaction with cash and Credit Facility proceeds. On January 14, 2026, it acquired Cambodian…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Charles River acquired an additional 79% interest in PathoQuest SAS on April 17, 2026, for $67.6 million, funded with cash and Credit Facility proceeds. It also acquired a Cambodian non-human-primate supplier on…
• Interest Rate and Refinancing ExposureImportance 71 · Surprise 48
  Charles River’s debt outstanding increased to $2.62 billion as of June 27, 2026, from $2.12 billion as of December 27, 2025, including $1.12 billion drawn on its revolving facility. The $2.0 billion multi-currency…
• Income Tax Rate ChangesImportance 65 · Surprise 82
  The second-quarter effective tax rate increased to 101.4% from 26.2%, while income tax expense increased $35.2 million to $53.9 million despite pretax income declining 25.6% to $53.2 million. For the first half, the…
• Operating Margin DriversImportance 64 · Surprise 56
  Six-month operating income increased 37.2% to $239.8 million and operating margin expanded 330 basis points to 12.0% from 8.7%. Second-quarter operating income increased 19.7% to $119.9 million and operating margin…
• Headcount and RestructuringImportance 64 · Surprise 42
  The company continues workforce right-sizing and site-optimization actions implemented over the past three years, including severance, transition costs, asset impairments, accelerated depreciation, and…
• Operating Cash Flow TrendsImportance 64 · Surprise 56
  Six-month operating cash flow decreased 41.3% to $220.8 million from $376.3 million in the prior-year period. The decline primarily reflected higher annual incentive bonus payments made in the first quarter and higher…
• Headcount / RestructuringImportance 64 · Surprise 42
  The company is implementing workforce right-sizing, site optimization, process improvements, procurement synergies, and a global business services model in response to demand conditions. These initiatives are expected…
• Capital Return ProgramImportance 58 · Surprise 42
  The board authorized a $1.0 billion stock repurchase program on October 29, 2025. During the six months ended June 27, 2026, Charles River repurchased 1.7 million shares for $300.0 million under the program, leaving…
• End-Market Demand TrendsImportance 55 · Surprise 32
  Charles River reported a cautious but improving client spending environment, with the most persistent demand challenges concentrated in the Discovery and Safety Assessment (DSA) segment. DSA backlog increased slightly…
• Market Demand TrendsImportance 55 · Surprise 32
  Charles River reported a cautious but improving client spending environment, with challenging demand persisting principally in the Discovery and Safety Assessment (DSA) segment during 2026. DSA backlog increased to…
• Revenue Performance and MixImportance 49 · Surprise 32
  Six-month revenue decreased 0.8% year over year to $1,999.9 million from $2,016.3 million, while second-quarter revenue decreased 2.7% to $1,004.1 million from $1,032.1 million. Six-month service revenue declined 2.0%…
• FX / Currency HeadwindsImportance 44 · Surprise 24
  Charles River operates globally with principal foreign-currency exposures in the Euro, Canadian Dollar, and British Pound, as well as the Mauritian Rupee, Chinese Yuan, and Hungarian Forint. Management estimates that a…
• Regulatory RiskImportance 37 · Surprise 42
  The company continues to incur costs related to investigations by the U.S. government into its non-human-primate (NHP) supply chain. Third-party legal costs associated with those investigations declined in the first…
• FX / Currency ImpactImportance 35 · Surprise 22
  The company estimates that a 10% strengthening of the U.S. dollar would have reduced six-month revenue by $91.6 million and operating income by $21.6 million, holding other variables constant. Foreign-currency…
• Products and TechnologyImportance 26 · Surprise 24
  Charles River’s Microbial Solutions business saw increased demand for endotoxin products during the quarter and first six months of 2026. The business provides in vitro lot-release testing products, microbial detection…
• Geographic Market CommentaryImportance 13 · Surprise 6
  Research Models and Services (RMS) experienced weaker demand in North America, including lower service revenue and lower large and small research model product revenue. This weakness was partially offset by increased…

Earnings call · 2026-08-05

• Guidance and OutlookImportance 69 · Surprise 68
  Management raised 2026 reported revenue guidance to a 2.5%–3.5% decline and organic revenue guidance to flat to 1% growth, a 150-basis-point improvement to the prior outlook. DSA organic revenue guidance was raised to…
• Operating Cash Flow TrendsImportance 64 · Surprise 40
  Second-quarter free cash flow was $149 million, down $21 million from the prior-year period. The decline was primarily caused by working-capital timing rather than a deterioration in operating performance. Full-year…
• Operating Expense TrendsImportance 57 · Surprise 48
  Unallocated corporate costs totaled $72 million, or 7.2% of revenue, versus 5.9% in the prior-year quarter. The increase primarily reflected $6 million of deferred-compensation-plan costs, equal to $0.10 per share,…
• DSA Order TrendsImportance 56 · Surprise 32
  DSA net bookings increased significantly year-over-year and 12.6% sequentially to $701 million in the second quarter. The DSA backlog rose to $1.97 billion, producing a 1.19x net book-to-bill, the highest level in…
• Portfolio Refinement and M&AImportance 53 · Surprise 60
  Charles River completed divestitures of certain European discovery-services sites and the CDMO and Cell Solutions businesses in May 2026. The divestitures produced a partial-quarter benefit in the second-quarter…
• Capital Return ProgramImportance 52 · Surprise 42
  Charles River repurchased $100 million of shares in the second quarter at approximately $174 per share. Year-to-date repurchases reached $300 million under the $1 billion authorization approved in October 2025.…
• Mauritius Tax LegislationImportance 51 · Surprise 60
  Management incorporated into 2026 guidance an expected tax increase associated with proposed legislation in Mauritius. The company expects a decision from local authorities imminently and has modeled the anticipated…
• NHP Regulatory Investigation ResolutionImportance 47 · Surprise 60
  Management said control of the nonhuman-primate supply chain is providing clients greater assurance that studies can begin when needed and without timing delays. Charles River manages when animals are brought in,…
• Operating Margin DriversImportance 42 · Surprise 40
  Non-GAAP operating margin increased 420 basis points sequentially to 20.5% in the second quarter. The improvement reflected reduced pressure from first-quarter discrete headwinds and partial-quarter benefits from…
• Income Tax Rate ChangesImportance 41 · Surprise 32
  The second-quarter non-GAAP tax rate increased 110 basis points year over year to 23.8%, primarily because of discrete items. Full-year non-GAAP tax-rate guidance increased to 23%–24%, approximately 100 basis points…
• Revenue Performance and MixImportance 37 · Surprise 32
  Second-quarter revenue was essentially flat organically year over year, with total-company organic revenue growth of 0.1%, the first organic improvement since the third quarter of 2023. DSA revenue was $607 million,…
• Digital Pathology AutomationImportance 34 · Surprise 42
  Charles River is investing in an enhanced digital pathology solution with AI-enabled, end-to-end workflows. The company has more than 140 trained pathologists, and management expects the technology to improve internal…
• Capital ExpendituresImportance 31 · Surprise 40
  Second-quarter capital expenditures declined to $31 million, or approximately 3.1% of revenue, from $35 million in the prior-year quarter. Charles River is continuing a global laboratory-expansion program focused on…
• Manufacturing And CapacityImportance 31 · Surprise 42
  Charles River is expanding bioanalytical laboratory capacity at Heriot-Watt University’s Research Park in Scotland. The Scotland project is one of five lab-sciences expansions underway globally and includes a potential…
• China Regulatory and Trade RiskImportance 31 · Surprise 42
  Management said Western clients have not yet materially moved regulated work to China following the U.S. Department of Defense list and WuXi’s inclusion on the no-entity list. Discussions with clients in the regulated…
• Strategic InitiativesImportance 31 · Surprise 42
  Charles River is investing in staffing, lab space, and laboratory expansions to support expected demand, including an expansion in Edinburgh near a university to assist with recruiting. Management said these expansions…
• NHP Supply SourcingImportance 30 · Surprise 42
  Demand remains strong for complex modalities and NHP-related studies, reflecting client focus on complex biologics and creating opportunities in both in vivo studies and associated bioanalysis. Charles River controls…
• Manufacturing Market DemandImportance 24 · Surprise 32
  Manufacturing demand increased across the company’s three major geographic regions, led by high-single-digit growth in Microbial Solutions. Demand was strongest for endotoxin-testing reagents, including PTS…
• Liquidity and Debt PositionImportance 19 · Surprise 6
  Net leverage improved slightly to 2.5x at the end of the second quarter, even after the company completed a $100 million share repurchase. Net interest expense was $28 million in the quarter, down $1.2 million year…
• Competition and Pricing PressureImportance 17 · Surprise 24
  Charles River is monitoring the increasing capabilities of Chinese CROs, particularly their potential expansion from early-stage chemistry and biology into regulated work. Management said regulated work remains a…
• China Early-Stage Market DemandImportance 17 · Surprise 24
  Charles River said most biotech work conducted in China is early-stage chemistry and biology, which is no longer part of its portfolio. Western clients remain uncertain and are taking a wait-and-see approach, with…
• RMS Geographic DemandImportance 14 · Surprise 6
  RMS revenue declined organically primarily because of lower volumes for small research models in North America and weaker research model services, including GEMS. These declines were largely offset by continued robust…
• China Market CommentaryImportance 10 · Surprise 6
  Management described China as an important and evolving market and said Charles River has a strong research-models and services business there. The company is monitoring the increasing capabilities of Chinese CROs and…
• Biotech Funding and DemandImportance 7 · Surprise 24
  Charles River said the biopharmaceutical demand environment continued to strengthen in the second quarter, led particularly by the DSA segment. Small and midsized biotech funding reached nearly $100 billion on a…
• AI Research PartnershipsImportance 6 · Surprise 42
  Charles River collaborated with Eli Lilly’s TuneLab drug discovery platform to provide nonclinical wet-lab testing expertise for Lilly’s AI and machine-learning drug discovery model. Management emphasized that…

8-K · 2026-08-05

• Operating Expense TrendsImportance 35 · Surprise 22
  Second-quarter selling, general and administrative expense increased to $228.9 million from $191.5 million, a $37.3 million or 19.5% year-over-year increase. Unallocated corporate overhead increased to $106.4 million…
• Products and TechnologyImportance 31 · Surprise 42
  Charles River joined Eli Lilly’s TuneLab AI/ML platform, contributing non-clinical testing expertise to drug-discovery optimization and R&D modernization. It collaborated with Arovella Therapeutics to provide in vitro…
• Manufacturing Market DemandImportance 31 · Surprise 32
  Manufacturing Solutions revenue was $188.1 million, down 6.3% year over year on a reported basis because of the CDMO divestiture. Organic Manufacturing revenue increased 1.3%, driven primarily by higher revenue in the…
• AI Research PartnershipsImportance 31 · Surprise 42
  Charles River joined Eli Lilly’s TuneLab AI/ML platform to provide non-clinical testing expertise for drug discovery and R&D modernization. It also collaborated with Arovella Therapeutics to provide in vitro Next…
• Digital Pathology AutomationImportance 31 · Surprise 42
  Charles River introduced an enhanced digital pathology solution as part of its modernization program. The solution uses artificial intelligence and is designed as an end-to-end workflow to digitize and automate…
• Operating Margin DriversImportance 29 · Surprise 22
  GAAP operating margin increased to 11.9% from 9.7% year over year, primarily because of the CDMO business and lower accelerated amortization for certain client relationships. Non-GAAP operating margin decreased to…
• Geographic Market CommentaryImportance 25 · Surprise 32
  Research Models and Services (RMS) organic revenue declined 1.4%, primarily because of lower small research model revenue in North America and lower research model services revenue. The North American weakness was…
• Research Models Market TrendsImportance 25 · Surprise 32
  RMS revenue declined 1.8% year over year to $209.5 million, with organic revenue down 1.4%. The decline was primarily attributable to lower demand for small research models in North America and lower research model…
• Revenue Performance and MixImportance 24 · Surprise 14
  Second-quarter revenue was $1.004 billion, down 2.7% year over year from $1.032 billion, while organic revenue increased 0.1%. Manufacturing Solutions revenue was $188.1 million, down 6.3% due primarily to the CDMO…
• Market Demand TrendsImportance 17 · Surprise 24
  Charles River reported that demand strengthened in the second quarter, with the highest net book-to-bill in nearly four years. Improvement was broad based across global biopharmaceutical clients and small and mid-sized…